Global News Roundup: Q2 2022

Articles
Written By Adam Foster

Windrose Consulting Group, Global News Roundup: Q2 2022

We are pleased to launch the next edition of our quarterly Windrose Consulting Group: Global News Roundup for Q2 2022

In this edition, we look at many key changes in the Global Life Sciences industry, such as: The Innovative Medicines Fund (IMF) is up and running in the UK; the FDA lays down criteria for single-country foreign data submissions; France makes changes to its early access program criteria for “innovativeness”; The Netherlands starts a new access management protocol for orphan drugs; plus more coverage from around the world.

Strategic guidance for Life Sciences.

Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize the commercial value of their products—so they can meet today’s most critical healthcare needs. We work across a broad range of products and disease areas with services that include product commercialization, pricing and market access and value communication. At Windrose, we’re committed to helping companies succeed in bringing innovations to market that enhance people’s lives. We work globally and have three offices, based in Philadelphia (US), London (UK) and Lucerne (Switzerland).

Adam Foster
Previous

The Foreign Data Problem: Implications of the FDA’s New Criteria for Foreign Data Submissions
Next

Q&A – with Daisy Pharoah, Analyst at Windrose Consulting Group